BioMarin Pharmaceutical (BMRN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$64.41-0.34%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
BioMarin grows revenue about 24% a year, helped by new rare disease treatments. Profit improved from a loss to $130M in Q1 2026. The company raised its 2026 revenue guidance to about $3.9 billion. Recent positive trial data supports future growth.
Competition in rare diseases could slow growth. The company missed Q1 earnings by 16.5%. Debt from recent deals may pressure cash flow. Profit margins could weaken if costs rise.
The market prices in about 24% revenue growth and values shares roughly 11% below our fair value near $72. Our fair value is 23% below the Street median, reflecting cautious optimism. We see risk from earnings misses and competition.
Breaks if: Competitors erode market share significantly
Breaks if: Operating income falls below breakeven next year
Revenue falls below $3.2B in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on biopharmaceutical growth. The current thesis state is intact, supported by strong recent financial performance and ongoing management priorities.
The market has a neutral valuation of BMRN, with expectations that are slightly below the average. There is a low fragility tier, indicating that the stock is not currently priced for significant negative surprises.
Fundamentals are likely to show continued revenue growth, particularly from the integration of the Amicus acquisition and key products like VOXZOGO. However, profitability may be impacted by ongoing integration costs and moderate risks in the near term.
The thesis hinges on management's ability to execute on growth strategies and navigate potential risks, such as guidance cuts or broader economic challenges. Additionally, the performance of sector peers could influence BMRN's momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. The company resolved patent litigation with Ascendis Pharma. This secured royalty revenue and strengthens its position. The integration of the Amicus acquisition should accelerate growth for key products.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Acquisition fails or integration disrupts growth
Over the next 1 to 3 years, BMRN's performance will depend on successful integration and growth of its product portfolio while managing risks. Not investment advice.